Medicinal products - Latest updates

Commission authorises first combined COVID-19 and influenza vaccine for people 50 years and older

Agenda - 103rd meeting of the Pharmaceutical Committee (27 March 2026)

Consultation of new guidance on the conduct of clinical trials during public health emergencies in the EU

Presentation and recording - EUHPP Live Webinar on Biosimilars policies and (best) practices - Evidence from the AUGMENT Biosimilar study (19 February 2026)

2024 annual report on the paediatric medicines regulation

Factsheet - Revolutionising Clinical Trials

New measures to make EU health sector more innovative, competitive and resilient

Summary report, presentations and video recording - Biosimilar medicines - Multistakeholder Event (4 December 2025)

Commission welcomes political agreement on major reform of EU pharmaceutical rules

Deadline for applications extended to 5 December 2025 - Civil Society representatives: Call for expressions of interest for the EMA PDCO Committee

Commission authorises first treatment for serious chronic lung disease

Agenda - Biosimilar medicines: Multistakeholder Event (4 December 2025)

New and updated documents - EudraLex Volume 10: Clinical trials guidelines

Statement by Commissioner Várhelyi ahead of the 30th anniversary of EU medicines approval

Commission publishes new measures for the better lifecycle management of medicine authorisations

Commission authorises medicine to treat postpartum depression

Stakeholders’ Consultation on EudraLex Volume 4 - Good Manufacturing Practice Guidelines: Chapter 1

Document summarising evidence supporting the legislative proposal for strengthening the availability, supply and production of critical medicines within the EU

Commission staff working document on the use of titanium dioxide in medicinal products